Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI
This trial compared standard therapy (dual antiplatelet therapy plus a vitamin K antagonist) with two regimens containing rivaroxaban plus antiplatelet therapy. The rivaroxaban groups had reduced rates of bleeding and similar efficacy in preventing cardiovascular events. Approximately 5 to 8% of pat...
Saved in:
Published in | The New England journal of medicine Vol. 375; no. 25; pp. 2423 - 2434 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Massachusetts Medical Society
22.12.2016
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | This trial compared standard therapy (dual antiplatelet therapy plus a vitamin K antagonist) with two regimens containing rivaroxaban plus antiplatelet therapy. The rivaroxaban groups had reduced rates of bleeding and similar efficacy in preventing cardiovascular events.
Approximately 5 to 8% of patients who undergo percutaneous coronary intervention (PCI) have atrial fibrillation.
1
–
3
Dual antiplatelet therapy (DAPT) with a P2Y
12
inhibitor and aspirin is superior to oral anticoagulation with a vitamin K antagonist in reducing the risk of thrombosis in patients undergoing placement of a first-generation stent,
4
but oral anticoagulation is superior to DAPT in reducing the risk of ischemic stroke in patients with atrial fibrillation.
5
The treatment strategy for patients with atrial fibrillation who have received stents must balance the risk of stent thrombosis and ischemic stroke with the risk of bleeding. A common guideline-supported . . . |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-News-2 ObjectType-Feature-3 content type line 23 |
ISSN: | 0028-4793 1533-4406 |
DOI: | 10.1056/NEJMoa1611594 |